What is eMolecules?
eMolecules operates at the intersection of data analytics and e-commerce within the life sciences industry. The company provides critical business intelligence and integrated software solutions designed to streamline the procurement and management of essential research materials, including screening compounds, chemical building blocks, and primary antibodies. By aggregating and analyzing supply chain data, eMolecules significantly empowers drug discovery researchers across various sectors such as pharmaceuticals, biotechnology, academia, contract research organizations (CROs), and agrochemicals. Founded in 2005 and headquartered in San Diego, with additional offices in Boston and London, the company employs over 50 professionals dedicated to advancing scientific research.
How much funding has eMolecules raised?
eMolecules has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in eMolecules
PPP
Public-Private Partnership
What's next for eMolecules?
With its recent capital injection and a clear focus on late-stage development, eMolecules is poised for significant growth. The company's strategic objective is to further enhance its data aggregation and analytical capabilities, thereby deepening its value proposition for drug discovery professionals. Future initiatives will likely involve expanding its service offerings, potentially integrating more advanced AI-driven insights into its platform, and broadening its market reach. The company's ability to provide actionable intelligence on supply chain dynamics for critical research materials positions it as a key enabler in the ongoing quest for novel therapeutics.
See full eMolecules company page
